172 related articles for article (PubMed ID: 33872388)
1. High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels.
Urick ME; Yu EJ; Bell DW
Cancer; 2021 Aug; 127(16):2905-2915. PubMed ID: 33872388
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Urick ME; Bell DW
Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
Urick ME; Bell DW
Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
[TBL] [Abstract][Full Text] [Related]
4. Druggable genetic targets in endometrial cancer
Lehrer S; Rheinstein PH
Cancer Treat Res Commun; 2022; 30():100502. PubMed ID: 34933203
[TBL] [Abstract][Full Text] [Related]
5. FBXW7, L1CAM, and TGM2 in endometrial cancer.
Lehrer S; Rheinstein PH
Cancer; 2021 Nov; 127(21):4103-4104. PubMed ID: 34324708
[No Abstract] [Full Text] [Related]
6. Reply to FBXW7, L1CAM, and TGM2 in endometrial cancer.
Urick ME; Yu EJ; Bell DW
Cancer; 2021 Nov; 127(21):4105. PubMed ID: 34324196
[No Abstract] [Full Text] [Related]
7. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis.
Brown M; Leon A; Kedzierska K; Moore C; Belnoue-Davis HL; Flach S; Lydon JP; DeMayo FJ; Lewis A; Bosse T; Tomlinson I; Church DN
EMBO Mol Med; 2023 Oct; 15(10):e17094. PubMed ID: 37589076
[TBL] [Abstract][Full Text] [Related]
8. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
[TBL] [Abstract][Full Text] [Related]
9. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
10. Alteration of tumor suppressors changes the endometrial tumor spectrum.
Mayo LD
EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.
Schirmer U; Fiegl H; Pfeifer M; Zeimet AG; Müller-Holzner E; Bode PK; Tischler V; Altevogt P
BMC Cancer; 2013 Mar; 13():156. PubMed ID: 23530769
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.
Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M
J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Baxter JS; Brough R; Krastev DB; Song F; Sridhar S; Gulati A; Alexander J; Roumeliotis TI; Kozik Z; Choudhary JS; Haider S; Pettitt SJ; Tutt ANJ; Lord CJ
Mol Oncol; 2024 Feb; 18(2):369-385. PubMed ID: 37866880
[TBL] [Abstract][Full Text] [Related]
14.
Close V; Close W; Kugler SJ; Reichenzeller M; Yosifov DY; Bloehdorn J; Pan L; Tausch E; Westhoff MA; Döhner H; Stilgenbauer S; Oswald F; Mertens D
Blood; 2019 Feb; 133(8):830-839. PubMed ID: 30510140
[No Abstract] [Full Text] [Related]
15. The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis.
Giannini A; D'Oria O; Corrado G; Bruno V; Sperduti I; Bogani G; Laganà AS; Chiantera V; Caserta D; Vizza E
Arch Gynecol Obstet; 2024 Mar; 309(3):789-799. PubMed ID: 37454351
[TBL] [Abstract][Full Text] [Related]
16. miR-205 promotes epithelial-mesenchymal transition by targeting AKT signaling in endometrial cancer cells.
Jin C; Liang R
J Obstet Gynaecol Res; 2015 Oct; 41(10):1653-60. PubMed ID: 26446417
[TBL] [Abstract][Full Text] [Related]
17. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
18. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
[TBL] [Abstract][Full Text] [Related]
19. Culture characters, genetic background, estrogen/progesterone receptor expression, and tumorigenic activities of frequently used sixteen endometrial cancer cell lines.
Qu W; Zhao Y; Wang X; Qi Y; Zhou C; Hua Y; Hou J; Jiang SW
Clin Chim Acta; 2019 Feb; 489():225-232. PubMed ID: 30107158
[TBL] [Abstract][Full Text] [Related]
20. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
